Literature DB >> 9365113

Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression.

J Luan1, R Shattuck-Brandt, H Haghnegahdar, J D Owen, R Strieter, M Burdick, C Nirodi, D Beauchamp, K N Johnson, A Richmond.   

Abstract

By reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, and immunohistochemistry, MGSA-alpha, -beta, -gamma, and CXCR2 mRNA expression and proteins are detected in 7 out of 10 human melanoma lesions. The biological consequence of constitutive expression of the MGSA/GRO chemokine in immortalized melanocytes was tested in SCID and nude mouse models. Continuous expression of MGSA/GRO-alpha, -beta, or -gamma in immortalized melan-a mouse melanocytes results in nearly 100% tumor formation for each of the clones tested, whereas clones expressing only the neomycin resistance vector form tumors <10% of the time. Moreover, antibodies to the MGSA/GRO proteins slow or inhibit the formation of tumors in the SCID mouse model and block the angiogenic response to conditioned medium from the tumor-producing clones. Transcription of the MGSA/GRO chemokines is regulated by an enhancesome-like complex comprised of the nuclear factor-kappaB (NF-kappaB), HMG(I)Y, IUR, and Sp1 elements. In Hs294T melanoma cells the half life of the IKB protein is shortened in comparison to normal retinal epithelial cells, facilitating the endogenous nuclear localization of NF-kappaB. We propose that this endogenous nuclear NF-kappaB, working in concert with the 115-kDa IUR-binding factor, promotes constitutive expression of MGSA/GRO genes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365113     DOI: 10.1002/jlb.62.5.588

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  70 in total

1.  Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.

Authors:  Wen-Jane Lee; Keng-Hsin Lan; Chiang-Ting Chou; Yu-Chiao Yi; Wei-Chih Chen; Hung-Chuan Pan; Yen-Chun Peng; Keh-Bin Wang; Yi-Ching Chen; Te-Hsin Chao; Hsing-Ru Tien; Wayne Huey Herng Sheu; Meei-Ling Sheu
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

Review 2.  Chemokines as mediators of angiogenesis.

Authors:  Borna Mehrad; Michael P Keane; Robert M Strieter
Journal:  Thromb Haemost       Date:  2007-05       Impact factor: 5.249

Review 3.  Chemokines as mediators of tumor angiogenesis and neovascularization.

Authors:  Ellen C Keeley; Borna Mehrad; Robert M Strieter
Journal:  Exp Cell Res       Date:  2010-10-30       Impact factor: 3.905

4.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 5.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

Review 6.  Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development.

Authors:  Yarí E Marín; Suzie Chen
Journal:  J Mol Med (Berl)       Date:  2004-08-21       Impact factor: 4.599

Review 7.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 8.  Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.

Authors:  Richard M Ransohoff
Journal:  Immunity       Date:  2009-11-20       Impact factor: 31.745

Review 9.  CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.

Authors:  Timothy R Donahue; O Joe Hines
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

10.  Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells.

Authors:  Jørn Henriksen; Marianne Stabell; Leonardo A Meza-Zepeda; Silje Au Lauvrak; Moustapha Kassem; Ola Myklebost
Journal:  BMC Cancer       Date:  2010-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.